Cencora Inc. Faces Antitrust Scrutiny Amid a $3.5 Billion Veterinary Asset Sale

The Federal Trade Commission’s (FTC) filing to block Cencora’s sale of its veterinary unit, MWI Veterinary Supply, to Covetrus represents the latest regulatory hurdle for the New York‑listed pharmaceutical and healthcare services firm. The $3.5 billion transaction, announced in a public filing on 13 November, would have transferred ownership of one of the country’s largest veterinary distributors from Cencora to Covetrus, a move that the FTC argues would substantially lessen competition in the U.S. veterinary supply chain.

Antitrust Rationale

The FTC’s complaint, filed in the U.S. District Court for the Southern District of New York, alleges that the merger would combine the two biggest distributors serving veterinary clinics and large corporate veterinary accounts. By eliminating a direct competitor, the deal could allow the merged entity to raise prices, lower service quality, and ultimately burden pet owners with higher costs. The agency’s position is reinforced by the support of attorneys general from eleven states, underscoring a broad governmental concern about potential market consolidation.

The commission voted 2‑0 to authorize staff to seek a permanent injunction that would halt the transaction. In its statement, the FTC emphasized that Covetrus and MWI are each other’s closest competitors in key veterinary distribution markets, and that the combined company would command an undue share of the market for veterinary supplies.

Covetrus’ Counter‑Argument

Covetrus responded with a press release on 13 November, arguing that the proposed merger would improve the economics of veterinary practices. The company stressed that veterinarians now have multiple avenues for procurement, including direct manufacturer sales, independent distributors, and online marketplaces that aggregate offers from more than 40 distributors and thousands of manufacturers. According to Covetrus, the combined entity would streamline access to products, technology, and support for practices, while maintaining service and supply‑chain reliability and driving down operating costs.

Covetrus’ statement also highlighted that the FTC’s case relies on a “narrow and outdated view of the market” and that veterinary clinics routinely switch suppliers, suggesting that a single large distributor would not dictate pricing or quality.

Implications for Cencora’s Stock

Wall‑Street analysts are divided. Some view the FTC action as a significant risk that could delay or derail the sale, potentially leaving Cencora with a large, costly asset that may not be fully monetized. Others believe that the company’s diversified portfolio—including its end‑to‑end commercialization solutions, over‑the‑counter products, and home‑healthcare supplies—provides sufficient resilience.

Cencora’s market cap of $68.5 billion and a trailing P/E of 19.94 place the company among the more favorably valued firms in the Health Care Providers & Services sector. Its share price, which closed at $359.03 on 12 November, sits comfortably within its 52‑week high of $377.54, yet remains above the low of $244.82 set in May. The company’s international distribution network and established brand suggest that, even if the FTC blocks the sale, Cencora may pursue alternative divestiture strategies or restructure its veterinary business to align with regulatory expectations.

Forward‑Looking Assessment

From an insider perspective, the FTC’s intervention signals that antitrust authorities remain vigilant over consolidations in niche healthcare segments. Cencora must therefore be prepared to defend the transaction through robust evidence of competitive benefits or negotiate a divestiture structure that mitigates the agency’s concerns. A successful resolution could unlock significant value for shareholders and reaffirm Cencora’s position as a leading player in the pharmaceutical and healthcare services arena. Conversely, an injunction could compel the company to reallocate capital, potentially impacting growth initiatives in its core commercialization and over‑the‑counter divisions.

In either scenario, the company’s ability to navigate regulatory scrutiny while maintaining operational momentum will be a key determinant of its near‑term valuation trajectory.